Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Short-Term Debt repayments (2018 - 2020)

Summit Therapeutics filings provide 3 years of Short-Term Debt repayments readings, the most recent being -$51000.0 for Q1 2020.

  • Quarterly Short-Term Debt repayments fell 148.97% to -$51000.0 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$999291.7 through Mar 2020, down 331.13% year-over-year, with the annual reading at -$435000.0 for FY2019, N/A changed from the prior year.
  • Short-Term Debt repayments hit -$51000.0 in Q1 2020 for Summit Therapeutics, up from -$730291.7 in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $117744.0 in Q2 2018 and bottomed at -$730291.7 in Q4 2019.
  • Average Short-Term Debt repayments over 3 years is -$70866.5, with a median of $26574.9 recorded in 2019.
  • The largest annual shift saw Short-Term Debt repayments tumbled 198.52% in 2019 before it tumbled 148.97% in 2020.
  • Summit Therapeutics' Short-Term Debt repayments stood at $105183.7 in 2018, then crashed by 794.3% to -$730291.7 in 2019, then surged by 93.02% to -$51000.0 in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Short-Term Debt repayments are -$51000.0 (Q1 2020), -$730291.7 (Q4 2019), and -$102000.0 (Q3 2019).